Suppr超能文献

肛门内括约管制动植入物治疗肛门失禁的长期疗效评估。

An evaluation of the long-term effectiveness of Gatekeeper™ intersphincteric implants for passive faecal incontinence.

机构信息

Department of Colorectal Surgery, Forth Valley Royal Hospital, Larbert, Stirlingshire, Scotland, UK.

Department of Surgery, University of Glasgow, Glasgow, Scotland, UK.

出版信息

Tech Coloproctol. 2022 Jul;26(7):537-543. doi: 10.1007/s10151-022-02630-z. Epub 2022 May 20.

Abstract

BACKGROUND

Implantation of Gatekeeper™ prostheses presents an option for the treatment of passive faecal incontinence (FI). Whilst preliminary results are encouraging, long-term data regarding its sustained benefit are limited. The aim of this study was to assess and evaluate the long-term clinical function and quality of life of patients with passive faecal incontinence who were treated with Gatekeeper™ prostheses.

METHODS

This was a single centre, single surgeon retrospective study of prospectively collected clinical data in patients with FI treated between June 2012 and May 2019. Patients with passive FI with symptoms refractory to conservative treatment and endoanal ultrasonography showing intact or disrupted internal anal sphincter were included. Formal clinical and quality of life assessments were carried out using the St. Mark's Incontinence Score (SMIS) and Faecal Incontinence Quality of Life (FIQoL) questionnaires at baseline, 3 months, 6 months, 12 months and then annually. Endoanal ultrasonography was performed both before and after surgery.

RESULTS

Forty patients (14 males, 26 females) with a median age of 62.5 (range 33-80) years were treated with the Gatekeeper™ implant. The majority of patients (87.5%) received six implants. There were no peri or post-operative complications. Prosthesis migration was observed in 12.5% patients. The median follow-up duration was 5 years (interquartile range (IQR) 3.25-6.00 years). A sustained improvement in median SMIS and FIQoL scores from baseline to follow-up was noted. Significant differences were observed between the median baseline SMIS score and last follow-up score of 16.00 (IQR 15.00-16.75) to 7.00 (IQR 5.00-8.00) respectively (p < 0.001), a 56.25% decrease. The overall median FIQoL score showed a significant improvement from 7.95 (IQR 7.13-9.48) to 13.15 (IQR 12.00-13.98) (p < 0.001) a 65.40% increase.

CONCLUSIONS

Gatekeeper™ implantation is a safe approach to treating passive FI and is minimally invasive, reproducible and has minimal complications. Long-term sustained clinical improvement is achievable beyond 5 years. Careful patient selection is paramount, as is consistency of technique and follow-up protocol.

摘要

背景

Gatekeeper™ 假体的植入为治疗被动性粪便失禁(FI)提供了一种选择。尽管初步结果令人鼓舞,但关于其持续获益的长期数据有限。本研究的目的是评估和评估接受 Gatekeeper™ 假体治疗的被动性 FI 患者的长期临床功能和生活质量。

方法

这是一项单中心、单外科医生回顾性研究,对 2012 年 6 月至 2019 年 5 月期间接受 FI 治疗的患者进行前瞻性收集的临床数据。纳入对保守治疗有反应且经肛超声显示完整或中断内肛括约肌的被动 FI 症状患者。在基线、3 个月、6 个月、12 个月以及随后每年进行正式的临床和生活质量评估,使用 St. Mark's 失禁评分(SMIS)和粪便失禁生活质量(FIQoL)问卷进行评估。在手术前后均进行经肛超声检查。

结果

40 名患者(14 名男性,26 名女性),中位年龄为 62.5 岁(范围 33-80 岁)。大多数患者(87.5%)接受了 6 个植入物治疗。没有围手术期并发症。12.5%的患者出现假体迁移。中位随访时间为 5 年(四分位距(IQR)3.25-6.00 年)。从基线到随访,SMIS 和 FIQoL 评分的中位数均持续改善。与基线 SMIS 评分和最后随访评分(分别为 16.00[IQR 15.00-16.75]至 7.00[IQR 5.00-8.00])相比,中位数显著降低(p<0.001),分别为 56.25%。总体 FIQoL 评分从 7.95(IQR 7.13-9.48)显著提高至 13.15(IQR 12.00-13.98)(p<0.001),增加了 65.40%。

结论

Gatekeeper™ 植入术是治疗被动性 FI 的一种安全方法,具有微创、可重复和并发症少的优点。5 年以上可实现长期持续临床改善。仔细选择患者至关重要,技术和随访方案的一致性也很重要。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a542/9213285/b5edc9d9387e/10151_2022_2630_Fig1_HTML.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验